CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 1, February 2012
22
AFRICA
9.
Ascensao A, Ferreira R, Magalhaes J. Exercise-induced cardioprotec-
tion – biochemical, morphological and functional evidence in whole
tissue and isolated mitochondria.
Int J Cardiol
2007;
12
; 117(1): 16–30.
10. Powers SK, Quindry JC, Kavazis AN. Exercise-induced cardioprotec-
tion against myocardial ischemia-reperfusion injury.
Free Radic Biol
Med
2008;
15
; 44(2): 193–201.
11. Okuda N, Hayashi T, Mori T,
et al.
Nifedipine enhances the cardiopro-
tective effect of an angiotensin-II receptor blocker in an experimental
animal model of heart failure.
Hypertens Res
2005;
28
: 431–438.
12. Packer M, O’Conner CM, Ghali JK,
et al
. Effect of amlodipine on
morbidity and mortality in severe chronic heart failure.
N Engl J Med
1996;
335
: 1107–1114.
13. Hasegawa H, Takano H, Kohro T,
et al
. Amelioration of hypertensive
heart failure by amlodipine may occur via antioxidative effects.
Hyper
tens Res
2006;
29
: 719–729.
14. Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. A
protein encoded within the Down syndrome critical region is enriched
in striated muscles and inhibits calcineurin signaling.
J Biol Chem
2000;
275
: 8719–8725.
15. Bradford MM. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding.
Anal Biochem
1979;
72
: 248–254.
16. Draper HH, Hadley M. Malondialdeyde determination as an index of
lipid peroxidation.
Meth Enzym
1990;
186
: 421–431.
17. Delmas-Beauvieux MC, Peuchant E, Dumon MF, Receuver MC, Le
Bras M, Clerc M. Relationship between red cell antioxidant enzymatic
system status and lipid peroxidation during the acute phase of malaria.
Clin Biochem
1995;
28
: 163–169.
18. Paglia DE, Valentine WN. Studies on the quantitative and qualitative
characterization of erythrocyte glutathione peroxidase.
J Lab Clin Med
1967;
70
: 158–169.
19. Chong TZ, Yang SP, Pei D. Amlodipine inhibits pro-inflammation
cytokines and free radical production and inducible nitric oxide
synthase expression in lipopolysaccharide/interferon
γ
stimulated
cultured vascular smooth muscle cells.
JJP
2002;
89
: 157–163.
20. Mancini GB. Antiatherosclerotic effects of calcium channel blockers.
Prog Cardiovasc Dis
2002;
45
: 1–2
21. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-
generation L-type calcium channel antagonists: ancillary actions of
amlodipine.
Arterioscler Thromb Vasc Biol
2003;
23
: 2155–2163.
22. Pereira B, Costa Rosa Lf, Safi DA, Medeiros MH, Curi R. Superoxide
dismutase, catalase, and glutathione peroxidase activities in muscle and
lymphoid organs of sedentary and exercise-trained rats.
Physiol Behav
1994;
56
: 1095–1099.
23. Sharrett, AR, Ballantyne CM, Coady SA,
et al.
Coronary heart
disease prediction from lipoprotein cholesterol levels, triglycer-
ides, lipoprotein(a), apolipoproteins A-I and B, and HDL density
subfractions: the Atherosclerosis Risk in Communities (ARIC) Study.
Circulation
2001;
104
: 1108–1113.
24. Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic
importance.
Chem Rev
2004;
104
: 119–137.
25. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases
endothelial superoxide anion production.
J Clin Invest
1993;
91
:
2546–2551.
26. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-
hydroxynonenal, malondialdehyde and related aldehydes.
Free Radical
Biol Med
1991;
11
: 81–128.
27. Kutuk O, Basaga H. Inflammation meets oxidation: NF-κB as a media-
tor of initial lesion development in atherosclerosis.
Trends Mol Med
2003;
9
: 549–557.
28. Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary
artery disease in hemodialysis patients.
Am J Nephrol
2004;
24
:
537–542.
29. Mogi M, Iwai M, Chen R,
et al
. Amlodipine treatment reduces stroke
size in apolipoprotein E-deficient mice.
Am J Hypertens
2006;
19
:
1144–1149.
30. Umemoto S, Kawahara S, Hashimoto R,
et al
. Different effects of
amlodipine and enalapril on the mitogen-activated protein kinase/
extracellular signal-regulated kinase pathway for induction of vascular
smooth muscle cell differentiation
in vivo
.
Hypertens Res
2006;
29
:
179–186.
31. Meilhac O, Ramachandran S, Chiang K, Santanam N, Parthasarathy S.
Role of arterial wall antioxidant defense in beneficial effects of exercise
on atherosclerosis in mice.
Arterioscler Thromb Vasc Biol
2001;
21
:
1681–1688.
32. Barry-Lane PA, Patterson C, van der Merwe M,
et al
. p47phox is
required for atherosclerotic lesion progression in ApoE−/−mice.
J Clin
Invest
2001;
108
: 1513–1522
33. Lundy A, Lutfi N, Beckey C. Review of nifedipine GITS in the treat-
ment of high risk patients with coronary artery disease and hyperten-
sion.
Vasc Health Risk Manag
2009;
5
: 429–440.
34. Umemoto S, Tanaka M, Kawahara S,
et al
. Calcium antagonist
reduces oxidative stress by upregulating Cu/Zn superoxide dismutase
in stroke-prone spontaneously hypertensive rats.
Hypertens Res
2004;
27
: 877–885.
35. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators
of angiogenesis signaling: role of NADPH oxidase.
Mol Cell Biochem
2004;
264
: 85–97.
36. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular
disease.
Arterioscler Thromb Vasc Biol
2005;
25
: 29–38.
37. Koyama Y, Takeishi Y, Takahashi H,
et al
. Azelnidipine inhibits H
2
O
2
-
induced cell death in neonatal rat cardiomyocytes.
Cardiovasc Drugs
Ther
2007;
21
: 69–72.
38. Masumoto K, Takeyasu A, Oizumi K, Kobayashi T. Studies of novel
1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of parti-
tion coefficient (log P) by high performance liquid chromatography
(HPLC).
Yakugaku Zasshi
1995;
115
: 213–220.
39. Tanaka T, Nangaku M, Miyata T,
et al
. Blockade of calcium influx
through L-type calcium channels attenuates mitochondrial injury and
apoptosis in hypoxic renal tubular cells.
J Am Soc Nephrol
2004;
15
:
2320–2333.
40. Candido R, Allen TJ, Lassila M,
et al.
Irbesartan but not amlodipine
suppresses diabetes-associated atherosclerosis.
Circulation
2004;
109
:
1536–1542.
